Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Bamlanivimab

- PMLiVE

Eli Lilly to acquire Protomer Technologies in a deal worth over $1bn

Protomer Technologies is a US biotech company focused on engineering glucose-responsive insulin

- PMLiVE

Breakthrough therapy designated for Lilly’s investigational Alzheimer’s drug donanemab

The BTD is based on data from the phase 2 TRAILBLAZER-ALZ study in early symptomatic Alzheimer's patients

- PMLiVE

Lilly showcases tirzepatide type 2 diabetes data at ADA 2021

Company is planning to submit the full data package for tirzepatide to regulatory authorities by the end of 2021

- PMLiVE

US pauses shipments of Eli Lilly’s COVID-19 antibody treatment due to variant concerns

Laboratory analyses found the therapy was not effective against variants first discovered in South Africa and Brazil

- PMLiVE

Eli Lilly demonstrates Verzenio win in high-risk breast cancer subset at ASCO

Verzenio plus endocrine therapy reduced the risk of patients developing metastatic disease by 39%

- PMLiVE

Lilly signs $1.25bn collaboration deal with MiNA Therapeutics

Lilly will pay MiNA $25m upfront as well as milestones payments of up to a total of $245m per target

- PMLiVE

bluebird bio aiming to separate business units by year-end

Biotech company has revealed that its new, separate oncology company will be named 2seventy bio

- PMLiVE

Eli Lilly/AbCellera’s COVID-19 variant-targeting antibody enters clinical trials

Drug will be evaluted alone and together with other monoclonal antibodies in the expanded BLAZE-4 trial

- PMLiVE

Pfizer’s COVID-19 vaccine yields $3.5bn in first quarter sales

Full-year guidance for BioNTech-partnered vaccine increased to $26bn

- PMLiVE

AstraZeneca reports ‘strong’ Q1 results, forecasts accelerated growth in 2021

Company is ‘well-positioned for a high growth year’, according to analyst

- PMLiVE

Gilead’s Q1 revenues lifted by COVID-19 med Veklury as HIV drugs take a hit

Total product sales excluding Veklury dropped by 11% to $4.9bn compared to Q1 2020

- PMLiVE

Lilly cuts 2021 guidance to reflect ‘lower expected revenue’ from COVID-19 antibody sales

FDA recently removed emergency authorisation for bamlanivimab monotherapy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links